Company intelligence / Profile preview

1Globe Biomedical

Beijing, Beijing Shi, China1globe-china.com ↗

Ownership: Private
Development stage: Other

Overview

The company has advanced small molecule and gene-targeting therapies for oncology and metabolic diseases. Its lead program, napabucasin, is in Phase 3 for metastatic colorectal carcinoma. Other assets include GH509 in Phase 2 for nonalcoholic steatohepatitis. Several programs have been discontinued or are at earlier stages. The company leverages proprietary platforms such as gene-silencing aiRNA, synthetic biology, and nanoparticle delivery technologies to develop first-in-class therapeutics targeting cancer stem cells and metabolic disorders.

Therapeutic areas: GastroenterologyOncology
Modalities: Small moleculeDNA drugRNA drugNanoparticle (RNA drug nanomaterial delivery technology)Synthetic biology treatment
Industry: Biotech

Partnerships

Previously with International Sumitomo Pharmaceutical Group/Dainippon Sumitomo Pharma for pipeline assets like BBI608/napabucasin.

Beyond the preview

Go deeper on 1Globe Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1Globe Biomedical.